Regina received a PhD in Cardiovascular Physiology/Pharmacology at the University of Gothenburg in 1993. She then continued in academia for eight years.
During this time she worked at the University of Gothenburg, University of Ottawa, University of Queensland and University of Nevada. In 1997 she became Associate Professor at the University of Gothenburg.
Regina has a broad scientific background in human and animal physiology, particularly in cardiovascular physiology. She has published over 60 papers and several review articles and book chapters within the field. She has detailed knowledge in the area of regenerative medicine, atherosclerosis, heart failure and cardiovascular physiology – including human disease pathophysiological mechanisms, medical need, current treatment and related pre-clinical science and capabilities.
During her nineteen years at AstraZeneca, Regina has held a number of increasingly senior roles spanning from project leader roles for drug projects from early target discovery up to Phase II in clinical development to line management and strategic responsibilities.
In January 2011, Regina was appointed Senior Director and strategy area lead for atherosclerotic cardiovascular disease and she was instrumental in establishing the Cardiac Regeneration research area focusing on heart failure. Regina also led AstraZeneca’s first mRNA programme, VEGF-A from start to Phase II clinical development. In 2014, she was appointed Head of Department Bioscience Heart Failure with overall accountability to initiate and progress the portfolio in the cardiovascular and heart failure area.
In 2017, Regina was appointed Vice President and in 2019 she was promoted to Senior Vice President and Global Head of Early Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D with accountabilities from target discovery through clinical proof of concept across small and large molecules leading a group of +340 individuals across all three R&D sites.
Searching for a cure for heart failure
Senior Director and strategic area leader for cardiac regeneration, 2013
Senior Director and strategic area leader for Atherosclerotic Cardiovascular Disease, 2010
PRESENTER AND PANELIST
Presenter and Panelist at the mRNA health conference Boston, 2014
Imaging of atherosclerosis using non-invasive ultrasound
Imaging of Atherosclerosis in WHHL rabbits using non-invasive ultrasound. Wetterholm R, Caidahl K, Volkmann R, Brandt-Eliasson U, Fritsche-Danielson R, Gan LM. Ultrasound Med Biol. 2007: 33(5):720-6
Non-invasive real-time imaging of atherosclerosis
Non-invasive real-time imaging of atherosclerosis in mice using ultrasound biomicroscopy. Gan, L-M., Grönros, J., Hägg, U., Wikström, J. Theodoropoulos, C, and Fritsche-Danielson R. Atherosclerosis 2007: 190(2):313-320.
Effect of metalloproteinase inhibition on atherosclerotic plaque stability
Effect of broad-spectrum matrix metalloproteinase inhibition on atherosclerotic plaque stability. Johnson, J L., Fritsche-Danielson, R., Behrendt, M. Westin- Eriksson, A., Wennbo, H., Herslöf, H., Elebring, M., George, S., McPheat, W. and Jackson, C L. Cardiovascular Research 2006: 71(3):586-595.
Role of ADAMTS-1 in Atherosclerosis
Role of ADAMTS-1 in Atherosclerosis: Remodeling of Carotid Artery, Immunohistochemistry, and Proteolysis of Versican. Jönsson-Rylander, A-C, Nilsson T., Fritsche-Danielson R, Hammarström A, Behrendt M, AnderssonJ-O, Lindgren K, Andersson A-K, Wallbrandt P, Brodin P, Thelin A, Westin a, Hurt-Camejo E, Lee-Søgaard C-H. Arteriosclerosis, Thrombosis & Vascular Biology 2005: 25(1):180-5.
We got some recent data on primary human cardiac progenitor-like cells, where we could actually show that these cells could proliferate and we are now characterizing these cells and studying if they can be differentiated into cardiomyocytes, endothelial cells and vascular smooth muscle cells.
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.